Pacific Edge - Latest News [Page 3]

Building Presence in World’s Largest Biomedical Market

Friday, 22 August 2014, 10:26 am | Pacific Edge

At its annual shareholders’ meeting held yesterday in Dunedin, New Zealand, cancer diagnostic developer, Pacific Edge, celebrated the commercial launch of its flagship bladder cancer diagnostic product, Cxbladder, into the US and provided shareholders ... More >>

Bladder cancer testing service goes live in NZ

Tuesday, 29 July 2014, 12:06 pm | Pacific Edge

All New Zealand residents and healthcare professionals can today access the Cxbladder cancer detection technology developed by Dunedin-based Pacific Edge with the ‘go live’ of an e-commerce platform. More >>

FY14 Marks Significant Commercial Milestone for Pacific Edge

Wednesday, 28 May 2014, 2:03 pm | Pacific Edge

The 2014 Financial Year marked a significant commercial milestone for Pacific Edge as the Company celebrated the start of revenue generation in its primary market, the USA, alongside a strong year of market development and customer capture. More >>

Pacific Edge signs Cxbladder agreement with MultiPlan

Monday, 26 May 2014, 10:38 am | Pacific Edge

Pacific Edge announced today that it has entered into a contractual agreement with MultiPlan, Inc. for diagnostics laboratory testing. The agreement includes Pacific Edge’s participation in the MultiPlan, PHCS and PHCS Savility Networks. More >>

Pacific Edge named Top Bioscience Company in 2014

Friday, 2 May 2014, 11:35 am | Pacific Edge

Pacific Edge has been named NZBIO’s top bioscience company for 2014. Pacific Edge was specifically recognised for building the profile and credibility of biotechnology and biotechnology companies in New Zealand. More >>

Callaghan Grant accelerates Cxbladder development

Thursday, 27 February 2014, 10:40 am | Pacific Edge

Pacific Edge is delighted to have the support of Callaghan Innovation to further accelerate the development of its molecular cancer detection technology. More >>

Commercial agreement for entry of Cxbladder to DHBs

Monday, 10 February 2014, 3:27 pm | Pacific Edge

10 February 2014 Health Innovation Hub signs commercial agreement for entry of Cxbladder to DHBs More >>

Pacific Edge shareholder rights offer closes

Thursday, 28 November 2013, 2:33 pm | Pacific Edge

Pacific Edge’s 2 for 15 pro rata renounceable rights offer of new Pacific Edge shares (“New Shares”) closed yesterday. More >>

PE signs Cxbladder agreement with 3rd national provider-US

Thursday, 28 November 2013, 12:33 pm | Pacific Edge

Pacific Edge has signed an agreement with Stratose, a large national provider network in the USA, to enable the provision of Cxbladder to patients through its large network of payers and providers. Stratose, one of the largest directly managed participating ... More >>

Pacific Edge - 2:15 pro-rata renounceable rights issue

Wednesday, 23 October 2013, 2:19 pm | Pacific Edge

Pacific Edge (NZX:PEB) announces a pro-rata renounceable rights issue to raise up to $20.5 million to further fund the roll out of its high performing cancer diagnostic system Cxbladder in the world’s largest health market, the USA. More >>

Pacific Edge signs agreement with American Network

Tuesday, 22 October 2013, 10:41 am | Pacific Edge

Pacific Edge signs agreement with America’s Choice Provider Network to expand access to Cxbladder in the US More >>

Cxbladder is Supreme Winner at NZ Innovators Awards

Friday, 18 October 2013, 1:02 pm | Pacific Edge

Pacific Edge is the 2013 Supreme Winner of the NZ Innovators Award for Cxbladder, its novel gene test for the detection and management of bladder cancer.' More >>

First Commercial Sales Achieved for Cxbladder in the USA

Friday, 18 October 2013, 11:52 am | Pacific Edge

Cancer diagnostic specialist Pacific Edge (NZX:PEB) is delighted to announce that it has completed the first commercial sales of Cxbladder tests signalling the start of the commercial revenue for the company in the US. The tests were ordered by US ... More >>

40 million Americans provided access to Cxbladder

Wednesday, 16 October 2013, 3:22 pm | Pacific Edge

Pacific Edge (NZX:PEB), a cancer diagnostic company leading in the development and commercialisation of molecular diagnostic tests, has signed an agreement with FedMed, a national preferred provider network in the United States, to make Cxbladder available ... More >>

US accolade with accreditation granted to Pacific Edge NZ

Wednesday, 2 October 2013, 12:09 pm | Pacific Edge

Cancer diagnostic specialist Pacific Edge has joined an elite group of organisations outside the United States with the registration of Pacific Edge Diagnostics’ Dunedin laboratory to conduct Cxbladder tests under the CLIA regulatory process. More >>

Cxbladder excels in New Zealand

Tuesday, 10 September 2013, 11:26 am | Pacific Edge

New Zealand clinicians and healthcare providers are excited about Pacific Edge Limited’s cancer detection system Cxbladder for its ability to detect bladder cancer with a high degree of accuracy. More >>

Pacific Edge appoints distinguished cancer researcher

Wednesday, 10 July 2013, 3:06 pm | Pacific Edge

Bryan Williams FRSNZ, FAA, who has a distinguished career in cancer research and international business, has accepted appointment to the Board of Pacific Edge Limited as an Independent Director. More >>

MidCentral DHB first in New Zealand to utilise Cxbladder

Thursday, 30 May 2013, 11:39 am | Pacific Edge

MidCentral District Health Board, based in Palmerston North, is set to become the first district health board in New Zealand to become a commercial customer for Pacific Edges diagnostic cancer test Cxbladder. MidCentral will be looking to provide patients ... More >>

China Grants Patent For Detection of Gastric Cancer

Thursday, 16 May 2013, 5:30 pm | Pacific Edge

China, with one of the highest incidences of stomach (Gastric) cancer in the world, has granted Pacific Edge Limited (the Company) its patent, ‘Detection of Gastric Cancer’. This patent defines technology that can be used for the diagnosis of gastric ... More >>

Pacific Edge’s US laboratory receives CLIA registration

Monday, 18 March 2013, 1:40 pm | Pacific Edge

Cancer diagnostic specialist Pacific Edge has achieved a major milestone with notification that its commercial laboratory in Hershey, Pennsylvania, has gained registration under the CLIA1 regulatory process clearing the way for the launch of Cx bladder ... More >>